News and Announcements
TAIM Investments achieves outstanding monthly performance in August & significant outperformance over 11 month
- Published September 06, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
The month of August saw most of Australia’s top listed companies report their FY2018 results with the ASX200 index continuing its recent positive performance advancing +0.6%, and the ASX200 Total Returns gaining +1.4%, during the month.
The relatively subdued nature of the general market, however, belied some significant individual stock price movements, both positive and negative, as companies reported results and updated their current outlook.
Both TAIM Funds had an outstanding month, continuing their significant outperformance of the broader market. Our TAIM Momentum Fund finished the month with an overall gain of +8.9%, and our TAIM Leverage Fund an exceptional +11.8%. Our since inception gains over 11 months now stand at +27.7% and +39.9% respectively.
About TAIM Investments
TAIM Investments operates two Australian equities investment funds. Both have exhibited exceptional performance, during an initial 4-year small-scale-offering period, and now under the company’s own AFSL. Both funds have an Australian blue chip focus – portfolio of 20 ASX200 equities, long only, no short-selling or derivatives – and we use an automated quantitative approach to deliver superior performance.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
